About us
Company Profile
Corporate culture
Executive leadership
Board of Directors
Investors
Our focus
Rare Neurological Diseases
Rare Metabolic and Endocrine Diseases
Rare Liver and Renal Diseases
Rare Pediatric Oncology Disease
Our science
Pipeline
Publications
Partnering
Partnership focus
Current partners
Media
Press releases
Corporate Presentations
Careers
Why Citrine
Contact us
Contacts
Headquarters & Branch Offices
EN
简
菜单
Search
Home
About us
Company Profile
Corporate culture
Executive leadership
Board of Directors
Investors
Our focus
Rare Neurological Diseases
Rare Metabolic and Endocrine Diseases
Rare Liver and Renal Diseases
Rare Pediatric Oncology Disease
Our science
Pipeline
Publications
Partnering
Partnership focus
Current partners
Media
Press releases
Corporate Presentations
Careers
Why Citrine
Contact us
Contacts
Headquarters & Branch Offices
EN
简
Media
Press releases
Corporate Presentations
2021-03-16
Citrine Medicine To Present at the 2021 WuXi Healthcare Forum and Participate in Two Additional Upcoming Healthcare Conferences
2021-01-27
Citrine Medicine Announces Strategic Partnership to bring Alkindi
®
to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
2021-01-08
Citrine Medicine to Participate at Three Upcoming Biotech Industry Conferences
2020-10-28
Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant)
2020-10-28
Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem
2020-07-13
Citrine Medicine, a Rare Disease Platform Company Focused on the China Market, Launches After Raising $80 Million in Series A Funding